SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/28/24 ATAI Life Sciences N.V. 10-K 12/31/23 110:26M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 5.07M 2: EX-4.2 Instrument Defining the Rights of Security Holders HTML 218K 3: EX-21.1 Subsidiaries List HTML 35K 4: EX-23.1 Consent of Expert or Counsel HTML 31K 9: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 53K Awarded Compensation 5: EX-31.1 Certification -- §302 - SOA'02 HTML 38K 6: EX-31.2 Certification -- §302 - SOA'02 HTML 38K 7: EX-32.1 Certification -- §906 - SOA'02 HTML 34K 8: EX-32.2 Certification -- §906 - SOA'02 HTML 34K 11: R1 Cover Page HTML 107K 12: R2 Condensed Consolidated Balance Sheets HTML 166K 13: R3 Condensed Consolidated Balance Sheets HTML 40K (Parenthetical) 14: R4 Consolidated Statements of Operations HTML 133K 15: R5 Consolidated Statements of Comprehensive Loss HTML 67K 16: R6 Condensed Consolidated Statements of Redeemable HTML 91K Noncontrolling Interests and Stockholders' Equity (Deficit) 17: R7 Condensed Consolidated Statements of Cash Flows HTML 160K 18: R8 Nature of Business HTML 40K 19: R9 Basis of Presentation, Consolidation and Summary HTML 135K of Significant Accounting Policies 20: R10 Dispositions HTML 47K 21: R11 Variable Interest Entities and a Voting Interest HTML 391K Entity 22: R12 Equity Method Investments and Other Investments HTML 208K 23: R13 Notes Receivable HTML 67K 24: R14 Fair Value Measurement HTML 277K 25: R15 Prepaid Expenses and Other Current Assets HTML 47K 26: R16 Accrued Liabilities HTML 49K 27: R17 Leases HTML 85K 28: R18 Debt HTML 99K 29: R19 Common Stock HTML 49K 30: R20 Stock-Based Compensation HTML 195K 31: R21 Income Taxes HTML 210K 32: R22 Net Loss Per Share HTML 75K 33: R23 Commitments and Contingencies HTML 41K 34: R24 License Agreements HTML 68K 35: R25 Related Party Transactions HTML 46K 36: R26 Defined Contribution Plan HTML 35K 37: R27 Corporate Restructuring HTML 39K 38: R28 Subsequent Events HTML 41K 39: R29 Basis of Presentation, Consolidation and Summary HTML 189K of Significant Accounting Policies (Policies) 40: R30 Variable Interest Entities and a Voting Interest HTML 379K Entity (Tables) 41: R31 Equity Method Investments and Other Investments HTML 137K (Tables) 42: R32 Fair Value Measurement (Tables) HTML 232K 43: R33 Prepaid Expenses and Other Current Assets (Tables) HTML 47K 44: R34 Accrued Liabilities (Tables) HTML 49K 45: R35 ROU assets and lease liabilities (Tables) HTML 43K 46: R36 Lease Costs (Tables) HTML 45K 47: R37 Future minimum commitments under all HTML 46K non-cancelable operating leases (Tables) 48: R38 Supplemental cash flow information related to the HTML 44K Company's operating lease (Tables) 49: R39 Debt (Tables) HTML 53K 50: R40 Stock-Based Compensation (Tables) HTML 177K 51: R41 Income Taxes (Tables) HTML 200K 52: R42 Net Loss Per Share (Tables) HTML 72K 53: R43 Nature of Business - Additional Information HTML 54K (Detail) 54: R44 Basis of Presentation, Consolidation and Summary HTML 60K of Significant Accounting Policies - Additional Information (Detail) 55: R45 Dispositions - Additional Information (Detail) HTML 43K 56: R46 Variable Interest Entities and a Voting Interest HTML 75K Entity - Additional information (Detail) 57: R47 Variable Interest Entities and a Voting Interest HTML 67K Entity - Summary of Primary Beneficiary for VIEs Consolidated Under the VIE Model (Detail) 58: R48 Variable Interest Entities and a Voting Interest HTML 136K Entity - Summary of the Assets and Liabilities for all Consolidated VIEs (Detail) 59: R49 Variable Interest Entities and a Voting Interest HTML 59K Entity - Schedule of Non Controlling Interest Recognized to Its Consolidated VIEs Roll Forward (Detail) 60: R50 Equity Method Investments and Other Investments - HTML 53K Summary of Equity Method Investments (Detail) 61: R51 Equity Method Investments and Other Investments - HTML 40K Summary of Equity Method Investments and Other Investments (Detail) 62: R52 Equity Method Investments and Other Investments - HTML 88K Summary of financial data for investments (Detail) 63: R53 Equity Method Investments and Other Investments - HTML 68K Summary of Statements of operations (Detail) 64: R54 Equity Method Investments and Other Investments - HTML 302K Additional information (Detail) 65: R55 Equity Method Investments and Other Investments - HTML 72K Securities Purchase Agreement - Additional information (Detail) 66: R56 Notes Receivable - Additional Information (Detail) HTML 195K 67: R57 Fair Value Measurement - Summary of Fair Value HTML 93K Measurement on Recurring Basis (Detail) 68: R58 Fair Value Measurement - Summary of Fair Value HTML 63K Measurement Inputs and Valuation Techniques (Detail) 69: R59 Fair Value Measurement - Summary of Fair Value HTML 73K Measurement on Recurring Basis, Unobservable Input Reconciliation (Detail) 70: R60 Fair Value Measurement - Additional Information HTML 105K (Detail) 71: R61 Prepaid Expenses and Other Current Assets - HTML 43K Summary of Prepaid Expenses and Other Current Assets (Detail) 72: R62 Accrued Liabilities - Summary of Accrued HTML 44K Liabilities (Detail) 73: R63 Leases (Additional Information) (Details) HTML 45K 74: R64 Leases - ROU assets and lease liabilities HTML 42K (Details) 75: R65 Leases - lease costs (Details) HTML 40K 76: R66 Leases - Future minimum commitments under all HTML 48K non-cancelable operating leases (Details) 77: R67 Leases - Supplemental cash flow information HTML 35K related to the Company's operating leases (Details) 78: R68 Debt - Summary of Convertible Promissory Notes HTML 42K (Detail) 79: R69 Debt - Additional Information (Detail) HTML 160K 80: R70 Debt - Schedule of Outstanding Debt Obligations HTML 53K (Detail) 81: R71 Debt- Summary of Grant Date Fair Value (Details) HTML 42K 82: R72 Common Stock - Additional Information (Detail) HTML 80K 83: R73 Stock-Based Compensation - Summary of share based HTML 81K Payment Arrangement Option Activity (Detail) 84: R74 Stock-Based Compensation - Summary of vested and HTML 60K non vested option outstanding (Parenthetical) (Details) 85: R75 Stock-Based Compensation - Schedule of Share-based HTML 55K Payment Award, Stock Options, Valuation Assumptions (Detail) 86: R76 Stock-Based Compensation - Summary of restricted HTML 54K stock unit activity (Details) 87: R77 Stock-Based Compensation - Summary of Employee HTML 76K Stock Ownership Plan (ESOP) Disclosures (Detail) 88: R78 Stock-Based Compensation - Summary of Share-based HTML 42K Compensation Arrangements by Share-based Payment Award (Detail) 89: R79 Stock-Based Compensation - Additional Information HTML 107K (Detail) 90: R80 Stock-Based Compensation - Summary of restricted HTML 54K stock awards (Details) 91: R81 Income Taxes - Additional Information (Detail) HTML 62K 92: R82 Income Taxes - Schedule of Income before Income HTML 42K Tax, German and Overseas (Details) 93: R83 Income Taxes - Schedule of Components of Income HTML 54K Tax Provision (Benefit) (Details) 94: R84 Income Taxes - Schedule of Effective Income Tax HTML 73K Rate Reconciliation (Details) 95: R85 Income Taxes - Summary of Components of Deferred HTML 68K Tax Assets and Deferred Tax Liabilities (Details) 96: R86 Income Taxes - Schedule of Gross Tax Loss HTML 37K Carryforward for Tax Return Purpose (Details) 97: R87 Income Taxes - Schedule of Unrecognized Tax HTML 40K Benefits (Details) 98: R88 Net Loss Per Share - Summary of Basic and Diluted HTML 77K Net Loss Per Share (Detail) 99: R89 Net Loss Per Share - Schedule of Potentially HTML 48K dilutive securities to the Company's common shares (Detail) 100: R90 Net Loss Per Share - Additional Information HTML 43K (Detail) 101: R91 License Agreements - Additional Information HTML 94K (Detail) 102: R92 Related Party Transactions - Additional HTML 65K Information (Detail) 103: R93 Defined Contribution Plan - Additional HTML 33K Information) (Details) 104: R94 Corporate Restructuring - Additional Information) HTML 49K (Details) 105: R95 Subsequent Events - Additional Information HTML 67K (Detail) 107: XML IDEA XML File -- Filing Summary XML 210K 110: XML XBRL Instance -- atai-20231231_htm XML 4.76M 106: EXCEL IDEA Workbook of Financial Report Info XLSX 292K 10: EX-101.SCH XBRL Taxonomy Extension Schema With Embedded XSD 7.77M Linkbases Document -- atai-20231231 108: JSON XBRL Instance as JSON Data -- MetaLinks 811± 1.31M 109: ZIP XBRL Zipped Folder -- 0000950170-24-038138-xbrl Zip 3.55M
EX-32.2 |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of ATAI Life Sciences N.V. (the “Company”) for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
Date: March 28, 2024 |
By: |
/s/ Anne Johnson |
|
|
|
|
|
Chief Financial Officer |
|
|
(Principal Financial Officer) |
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 3/28/24 | 8-K | ||
For Period end: | 12/31/23 | |||
List all Filings |